Acute treatment of migraine

Handbook of Clinical Neurology

Volumn 97, Issue C, 2010, Pages 323-336

  Brandes, J L ^a   Buchanan, T M ^b   Welch, K M A ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

HEADACHE; HUMAN; MIGRAINE;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HEADACHE; HUMANS; MIGRAINE DISORDERS; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

EID: 77956285361     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(10)97026-7     Document Type: Book

References (119)

1. Afra J., Mascia A., Gerard P., et al. Interictal cortical excitability in migraine: a study using transcranial magnetic stimulation of motor and visual cortices. Ann Neurol 1998, 44:209-215.
2. Ahn A.H., Fields H.L., Basbaum A.I. The triptan receptor 5HT1D is dynamically regulated in the central terminal of primary afferents in models of pain. Neurology 2004, 62:A440-444.
3. Akerman S., Goadsby P.J. The role of dopamine in a model of trigeminovascular nociception. J Pharmacol Exp Ther 2005, 314:162-169.
4. Akerman S., Kaube H., Goadsby P.J. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 2004, 309:56-63.
5. Alam Z., Coombes N., Waring R.H., et al. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 1998, 156:102-106.
6. Arulmani U., Heiligers J.P., Centurion D., et al. Lack of effect of the adenosine A1 receptor agonist, GR79236, on capsaicin-induced CGRP release in anaesthetized pigs. Cephalalgia 2005, 25:1082-1090.
7. Bigal M.E., Bordini C.A., Tepper S.J., et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 2002, 22:345-353.
8. Bland-Ward P.A., Feniuk W., Humphrey P.P.A. The adenosine A1 receptor agonist GR79236 inhibits evoked firing of trigeminal nucleus caudalis (TNC) neurons in the rat (Abstract). Cephalalgia 2000, 20:271.
9. Boska M.D., Welch K.M., Barker P.B., et al. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002, 58(8):1227-1233.
10. Bowyer S.M., Aurora S.K., Moran J.E., et al. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001, 50(5):582-587.
11. Brandes J.L., Kudrow D., Stark S.R., et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007, 297(13):1443-1454.
12. Buchan P., Keywood C., Wade A., et al. Clinical pharmacokinetics of frovatriptan. Headache 2002, 42(Suppl. 2):S54-S62.
13. Burstein R., Yarnitsky D., Goor-Aryeh I., et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
14. Burstein R., Collins D., Yakubowski M. Defeating migraine pain with triptan: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55(1):19-26.
15. Cady R.K., Lipton R.B., Hall C., et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000, 40(10):792-797.
16. Cananzi A.R., D'Andrea G., Perini F., et al. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 1995, 15:132-135.
17. Cerbo R., Barbanti P., Buzzi M.G., et al. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 1997, 20:36-41.
18. Cete Y., Dora B., Ertan C., et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. Metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2005, 25:199-204.
19. Classey J.D., Knight Y.E., Goadsby P.J. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res 2001, 907:117-124.
20. Cutrer F.M., Moskowitz M.A. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996, 36:579-585.
21. Cutrer F.M., Yu X.J., Ayata G., et al. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 1999, 38:1043-1053.
22. + pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003, 33(2):192-196.
23. Del Zompo M. Dopaminergic hypersensitivity in migraine: clinical and genetic evidence. Funct Neurol 2000, 15(Suppl. 3):163-170.
24. Diamond S., Freitag F., Phillips S., et al. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 2000, 20:597-602.
25. Dodick D.W. Triptans and chest symptoms: the role of pulmonary vasoconstriction. Cephalalgia 2004, 24:298-304.
26. Edvinsson L. New therapeutic target in primary headaches - blocking the CGRP receptor. Expert Opin Ther Targets 2003, 7:377-383.
27. Edvinsson L., Brodin E., Jansen I., et al. Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. Regul Pept 1988, 20:181-197.
28. Edvinsson L., Mulder H., Goadsby P.J., et al. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst 1998, 70:15-22.
29. Feindel W., Penfield W., McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960, 10:555-563.
30. Ferrari M.D. Migraine. Lancet 1998, 351:1043-1051.
31. Ferrari M.D., Odink J., Bos K.D., et al. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990, 40:1582-1586.
32. Ferrari M.D., Roon K.I., Lipton R.B., et al. Oral triptans (serotonin 5-HT agonists) in acute migraine treatment. Lancet 2001, 358:1668-1675.
33. Freitag F.G. Divalproex in the treatment of migraine. Psychopharmacol Bull 2003, 37(Suppl. 2):98-115.
34. Gallai V., Sarchielli P., Floridi A., et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995, 15:384-390.
35. Goadsby P.J., Classey J.D. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res 2000, 875:119-124.
36. Goadsby P.J., Hoskin K.L. The distribution of trigeminovascular afferents in the non-human primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997, 190:367-375.
37. Goadsby P.J., Edvinsson L., Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988, 23:193-196.
38. Goadsby P.J., Hoskin K.L., Storer R.J., et al. Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002, 125:1392-1401.
39. Goldstein D.J., Roon K.I., Offen W.W., et al. Selective serotonin 1F (5HT(1F)) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 2001, 358:1230-1234.
40. 1D agonist, in patients with acute migraine. Cephalalgia 2001, 21:727-732.
41. Hamel E., Saxena P.R. 5-Hydroxytryptamine involvement in migraine. The Headaches 2006, 275-280. Lippincott Williams & Wilkins, Philadelphia. 3rd edn. J. Olesen, P.J. Goadsby, N.M. Ramadan (Eds.).
42. Helyes Z., Pinter E., Nemeth J., et al. Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Br J Pharmacol 2001, 134:1571-1579.
43. Hjorth-Lassen L., Klingenberg Iversen H., Olesen J. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. Eur J Clin Pharmacol 2003, 59:499-505.
44. Ho T.W., Mannix L.K., Fan X., et al. Randomized controlled trial of an oral CGRP receptor antaganist, MK-0974, in acute treatment of migraine 2008, 70(16):1304-1312.
45. Hoyer D., Bell G.I., Berelowitz M., et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995, 16:86-88.
46. Hu X.H., Raskin N.H., Cowan R., et al. Treatment of migraine with rizatriptan: when to take the medication. Headache 2002, 42:16-20.
47. Humphrey P.P., Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991, 2:444-446.
48. Jansen-Olesen I., Jorgensen L., Engel U., et al. In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 2003, 481:207-216.
49. Jen J.C., Wan J., Palos T.P., et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005, 65:529-534.
50. Kaube H., Hoskin K.L., Goadsby P.J. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993, 109:788-792.
51. Kaube H., Herzog J., Kaufer T., et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000, 55:139-141.
52. Kaube H., Katsarava Z., Kaufer T., et al. A new method to increase the nociception specificity of the human blink reflex. Clin Neurophysiol 2000, 111:413-416.
53. Kaube H., Katsarava Z., Przywara S., et al. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus?. Neurology 2002, 58(8):1234-1238.
54. Keam S.J., Goa K.L., Figgitt D.P. Spotlight on almotriptan in migraine. CNS Drugs 2002, 16(7):501-507.
55. Klassen A., Elkind A., Asgharnejad M., et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind placebo-controlled, parallel group study. Naratriptan S2WA3001 study group. Headache 1997, 37(10):640-645.
56. Lange R., Schwarz J.A., Hohn M. Acetylsalicylic acid effervescent 1000 mg (aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000, 20(7):663-667.
57. Lassen L.H., Ashina M., Christiansen I., et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998, 18:27-32.
58. Lassen L.H., Jacobsen V.B., Petersen P., et al. Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs. Eur J Neurol 1998, 5(Suppl. 3):S63. 28.
59. Lassen L.H., Haderslev P.A., Jacobsen V.B., et al. CGRP may play a causative role in migraine. Cephalalgia 2002, 22:54-61.
60. Levy M.J., Matharu M.S., Bhola R., et al. Octreotide is not effective in the acute treatment of migraine. Cephalalgia 2005, 25:48-55.
61. Linder S.L., Mathew N.T., Cady R.K., et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008, 48(9):1326-1336.
62. Lipton R.B., Silberstein S. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 2001, 56(Suppl. 1):S35-S42.
63. Lipton R.B., Stewart W.F. Clinical application of zolmitriptan (311C90). Cephalalgia 1997, 17(18):53-59.
64. Lipton R.B., Stewart W.F., Stone A.M., et al. Disability in Strategies of Care Study Group. Stratified care vs. step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000, 284:2599-2605.
65. Liu-Chen L.-Y., Gillespie S.A., Norregaard T.V., et al. Co-localization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral. J Comp Neurol 1984, 225:187-192.
66. Longmore J., Dowson A.J., Hill R.G. Advances in migraine therapy - 5-HT receptor subtype-specific agonist drugs. Curr Opin CPNS Invest Drug 1999, 1:39-53.
67. Ma Q.P. Co-localization of 5-HT (1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001, 12:1589-1591.
68. Matharu M.S., Levy M.J., Meeran K., et al. Subcutaneous octreotide in cluster headache-randomized placebo-controlled double-blind cross-over study. Ann Neurol 2004, 56:488-494.
69. McCulloch J., Uddman R., Kingman T.A., et al. Calcitonin gene-related peptide: functional role in cerebro-vascular regulation. Proc Natl Acad Sci U S A 1986, 83:5731-5735.
70. McNeely W., Goa K.L. Diclofenac-potassium in migraine: a review. Drugs 1999, 57(6):991-1003.
71. Mitsikostas D.D., Sanchez del Rio M., Waeber C., et al. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998, 76:239-248.
72. Mitsikostas D.D., Sanchez del Rio M., Waeber C., et al. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 1999, 127:623-630.
73. Moskowitz M.A. (1990). Basic mechanisms in vascular headache. Neurol Clin 1990, 8:801-815.
74. Nozaki K., Moskowitz M.A., Boccalini P. CP-93, 129, sumatriptan, dihydroergotamine block c-fos expression within the rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992, 106:409-415.
75. Olesen J., Iverson H.K., Thomsen L.L. Nitric oxide supersensitivity. A possible molecular mechanism of migraine pain. Neuroreport 1993, 4:1027-1030.
76. Olesen J., Diener H.C., Husstedt I.W., et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350:1104-1110.
77. 2+ channel gene CACNLA4. Cell 1996, 87:543-552.
78. Pascual J., Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002, 42(1):28-31.
79. Patel Y.C., Srikant C.B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994, 135:2814-2817.
80. Peroutka S.J. Dopamine and migraine. Neurology 1997, 49:650-656.
81. Peroutka S.J. Neurogenic inflammation and migraine: implications for the therapeutics. Mol Intervent 2005, 304-311.
82. Petersen K.A., Birk S., Doods H., et al. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004, 143:697-704.
83. Potrebic S., Ahn A.H., Skinner K., et al. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003, 23:10988-10997.
84. Pregenzer J.F., Alberts G.L., Im W.B., et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol 1999, 127:468-472.
85. Quartu M., Serra M.P., Ambu R., et al. AMPA-type glutamate receptor subunits 2/3 in the human trigeminal sensory ganglion and subnucleus caudalis from prenatal ages to adulthood. Mech Ageing Dev 2002, 123:463-471.
86. Ramadan N.M. The link between glutamate and migraine. CNS Spectr 2003, 8:446-449.
87. 1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia 2003, 23:776-785.
88. Raskin N.H. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986, 36(7):995-997.
89. Read S.J., Smith M.I., Hunter A.J., et al. Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anaesthetized cat. Cephalalgia 1997, 17:159-165.
90. Reuter U., Bolay H., Jansen-Olesen I., et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001, 124:2490-2502.
91. Roon K.I., Olesen J., Diener H.C., et al. No acute antimigraine efficcy of CP-122, 288, a highly potent inhibitor of neurogenic inflammation: results of two randomized double-blind placebo-controlled clinical trials. Ann Neurol 2000, 47:238-241.
92. Roy A., Brand N.J., Yacoub M.H. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 2000, 9:256-260.
93. Ryan R.E. Patient treatment preferences and the 5HT 1B/1D agonists. Arch Intern Med 2001, 161(21):2545-2553.
94. Sahara Y., Noro N., Iida Y., et al. Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 1997, 17:6611-6620.
95. Sang C.N., Hostetter M.P., Gracely R.H., et al. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998, 89:1060-1067.
96. Sang C.N., Ramadan N.M., Wallihan R.G., et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004, 24:596-602.
97. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998, 17:1-11.
98. Saxena P.R., Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraines. The Headaches 2006, 469-503. Lippincott Williams & Wilkins, Philadelphia. 3rd edn. J. Olesen, P.J. Goadsby, N.M. Ramadan (Eds.).
99. Schindler M., Holloway S., Hathway G., et al. Identification of somatostatin sst2(a) receptor expressing neurones in central regions involved in nociception. Brain Res 1998, 798:25-35.
100. Schindler M., Harris C.A., Hayes B., et al. Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett 2001, 297:211-215.
101. Shepheard S., Edvinsson L., Cumberbatch M., et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 1999, 19:851-858.
102. Sicuteri F., Geppetti P., Marabini S., et al. Pain relief by somatostatin in attacks of cluster headache. Pain 1984, 18:359-365.
103. Silberstein S.D., Young W.B., Mendizabal J.E., et al. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology 2003, 60:315-321.
104. Syrett N., Abu-Shakra S., Yates R. Zolmitriptan nasal spray: advances in migraine treatment. Neurology 2003, 61(8 Suppl. 4):S27-S30.
105. Takiya L., Piccininni L.C., Kamath V. Safety and efficacy of eletriptan in the treatment of acute migraine. Pharmacotherapy 2006, 26(1):115-128.
106. Tallaksen-Greene S.J., Young A.B., Penney J.B., et al. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett 1992, 141:79-83.
107. Tanen D.A., Miller S., French T., et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 2003, 41:847-853.
108. Tassorelli C., Joseph S.A., Buzzi M.G., et al. The effects on central nervous system of nitroglycerin-putative mechanism and mediators. Prog Neurobiol 1999, 57:607-624.
109. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine: an international study. Headache 1998, 38(3):173-183. The International 311C90 Long-term Study Group.
110. Uddman R., Edvinsson L., Ekman R., et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985, 62:131-136.
111. Waeber C., Moskowitz M.A. Migraine as an inflammatory disorder. Neurology 2005, 64(10 Suppl. 2):S9-S15.
112. Watling K.J. Vanilloid receptors. The Sigma-RBI Handbook of Receptor Classification and Signal Transduction 2001, 143-144. Sigma-RBI, Natick, MA. K.J. Watling (Ed.).
113. Wei E.P., Moskowitz M.A., Baccalini P., et al. Calcitonin gene related peptide mediates nitroglycerin and sodium nitroprusside induced vasodilation in feline cerebral arteries. Circ Res 1992, 70:1313-1319.
114. Weiller C., May A., Limmroth V., et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658-660.
115. Welch K.M.A. Drug therapy of migraine. N Engl J Med 1993, 329(20):1476-1483.
116. Welch K.M.A. Contemporary concepts of migraine pathogenesis. Neurology 2003, 61(8 Suppl 4):S2-S8.
117. Welch K.M.A., Mathew N.T., Stone P., et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000, 20(8):687-695.
118. Welch K.M.A., Nagesh V., Aurora S.K., et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache 2001, 4(1):629-637.
119. Wellington K., Plosker G.L. Rizatriptan: an update of its use in the management of migraine. Drugs 2002, 62(10):1539-1574.